Monday, September 27, 2021
News

Covaxin effective against Delta Plus variant: ICMR

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

New Delhi | Monday, 2021 9:15:06 PM IST
The domestically developed Covaxin is effective against the Delta plus variant of Covid-19, claims Indian Council of Medical Research (ICMR) in its study released on Monday.

Covaxin is developed by the Bharat Biotech in collaboration with ICMR and National Institute of Pune.

The study states: "The sera of individuals who were fully immunized (with 2 doses) didn't show significant fold-reduction in the NAb titer against Delta, Delta AY.1 and B.1.617.3."

Delta Plus is a mutated form of the Delta variant and was first discovered in India. It is characterised by increased transmissibility and spike protein mutations.

The study points that Delta variant with its characteristic spike protein mutations has mutated further into four sub-lineages with an additional mutations which are associated with higher transmission and probable immune escape.

Last week, Union Science and Technology Minister Jitendra Singh informed parliament last week that 70 cases of the Delta Plus variant were found by INSACOG, a group of 28 laboratories involved in genome sequencing.

Covaxin along with other two vaccines -- Covishield and Russia's Sputnik -- has formed the trio for India's massive vaccination drive against the virus.

The research further states, "A significant increase in the NAb titer against B.1 variant in recovered cases with vaccination and breakthrough cases was observed compared to the Covid-19 native vaccines. Similarly, a significant increase in NAb titer was also observed among these two groups against Delta, Delta AY.1 and B.1.617.3 variants."

"This demonstrates the possible role of memory cells in immune boosting with post-infection or infection after immunization. The comparative analysis of all the groups revealed that the B.1.617.3 variant seems to be less susceptible to neutralization followed by Delta AY.1 and Delta variants."

The study on efficacy analysis further establishes Covaxin to be 93.4 per cent effective against severe symptomatic Covid-19 cases and 63.6 per cent protection against asymptomatic Covid-19.

--IANS avinash/sk/in

( 321 Words)

2021-08-02-15:08:02 (IANS)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
Africa's Covid cases near 8.27 million...
73% in 12 Odisha dists develop antibody ...
175 Covid recoveries, 127 new cases in J...
If second vaccine dose missed, process m...
Study finds higher dairy fat intake can ...
India logs 28,326 fresh cases, over 85 C...
More...
 
INDIA WORLD ASIA
Vice President Naidu on 5-day visit to R...
Karnataka: Kalaburagi City Corporation i...
YSRCP's farmers wing backs Monday's Bhar...
Bharat Bandh to bring Kerala to a grindi...
Landfall process of Cyclone Gulab begins...
Telangana districts alerted over impact ...
More...    
 
 Top Stories
Sydney Sixers sign Shafali Verma, R... 
Taliban appreciates Pakistan for su... 
We are genetically coordinated: Sha... 
History will look at this year as i... 
South Korea reports 2,383 more COVI... 
IPL 2021: We have not seen aggressi... 
Moeen Ali to announce retirement fr... 
Cyclone Gulab makes landfall, heavy...